Roche and Plexxikon's drug reduces melanoma tumors in a study

08/25/2010 | Reuters

Preliminary findings from an early-stage trial show that Roche Holding and Plexxikon's experimental drug PLX4032 shrank tumors in 81% of 32 patients with advanced melanoma who carry a mutated BRAF gene. Researchers are hoping to combine the treatment, which is in late-stage development, with other drugs to produce a long-lasting effect.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC